search
Back to results

Early Elimination of Premature Ventricular Contractions in Heart Failure (EVAC-HF)

Primary Purpose

Premature Ventricular Contractions, Congestive Heart Failure

Status
Terminated
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
PVC ablation
Sponsored by
University of Maryland, Baltimore
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Premature Ventricular Contractions focused on measuring ablations, CHF, PVC

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with reduced ejection fraction (EF ≤45%) demonstrated by transthoracic echocardiogram and deemed to be non-ischemic by nuclear stress test or cardiac catheterization.
  • Patients with >20% PVCs on 24 hour holter-recording
  • Patient is 18 years of age or older
  • Optimized medical therapy on stable therapy for minimum 3 months with no changes in beta-blocker, ACE-I/ARB, digoxin doses (varying diuretic doses permitted).

Exclusion Criteria:

  • Patients who are under the age of 18 years of age
  • Patients with >2 dominant PVC morphologies
  • Patients with cardiac surgery in previous 3 months or scheduled for following 6 months
  • Patients who were implanted with a biventricular device during the last three months or single/dual chamber device (with ventricular pacing >10%) during the last three months
  • Significant symptoms associated with PVCs that would make favor immediate ablation
  • Intracardiac mural thrombus or myxoma
  • Pregnancy

Sites / Locations

  • UCLA
  • University of Maryland Medical Center
  • University maryland medical Center
  • Brigham and Women's Hospital
  • University of Michigan
  • Ohio State University
  • University of Pennsylvania
  • University of Quebec

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

ablation procedure vs medical therapy

Compare 2 arms for safety, symptoms

Arm Description

PVC ablation vs medical therapy

Compare control of PVC's between 2 groups.

Outcomes

Primary Outcome Measures

Change of Left Ventricular Ejection Fraction Measured With Simpson's Rule Expressed in Percent From Pre to Post Intervention
Left ventricular ejection fraction with Simpson's Rule. This is a measurement obtained on an echocardiogram. It reflects the percentage of blood that is ejected from the heart with each beat. The mean change in ejection fraction will be compared for the 2 groups

Secondary Outcome Measures

Full Information

First Posted
December 3, 2012
Last Updated
February 25, 2021
Sponsor
University of Maryland, Baltimore
Collaborators
Biosense Webster, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01757067
Brief Title
Early Elimination of Premature Ventricular Contractions in Heart Failure
Acronym
EVAC-HF
Official Title
EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Terminated
Why Stopped
Unable to recruit sufficient participants
Study Start Date
January 2013 (undefined)
Primary Completion Date
May 17, 2017 (Actual)
Study Completion Date
May 17, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Maryland, Baltimore
Collaborators
Biosense Webster, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Premature ventricular contractions (PVC) are a very common irregular heart beat (arrhythmias) even in patients without heart disease. Frequent PVCs are thought to occur in about 1-4% of the general population. Many patients with PVCs complain about skipping of their heart (palpitations), shortness of breath and feeling tired. In some patients PVCs may also result in weakening of the heart muscle (heart failure), which might be reversible with suppression of the PVCs.
Detailed Description
A common way to get rid of PVCs is an ablation procedure during which a small area of heart muscle that creates the PVCs is cauterized, so that it can no longer cause PVCs. This has been performed for many years and is an overall safe and effective procedure to eliminate PVCs. In the ablation, a catheter with an electrode at its tip is guided with moving X-rays (fluoroscopy) displayed on a video screen to the exact site inside the heart where cells give off the electrical signals that stimulate the abnormal heart rhythm. Radiofrequency energy (similar to microwave heat) is transmitted from the catheter tip to the area. This destroys carefully selected heart muscle cells in a very small area (about 1/5 of an inch) and can stop the area from creating the extra impulses that cause the extra heartbeats. Additionally, some medications have the ability to suppress PVCs (antiarrhythmic medications). PVC ablation and antiarrhythmic medications have both been used to treat patients with PVC's and a reduced heart function. The heart function is referred to as ejection fraction (measured by cardiac ultrasound (echocardiogram). In this study it will be required the ejection fraction will be less than less than or equal to 45% (with 55% or more being normal). If enrolled in the study there is a 50/50 chance (like a coin toss and referred to as randomization) that the patient will either continue on the best currently available medical treatment for a weak heart muscle (as determined by the doctor) or will undergo a PVC catheter ablation (with a possible second ablation or antiarrhythmic medication, if the first ablation was not a success). All patients in the study will continue to take the best possible medications for the heart muscle weakness. If the patient is randomized to not undergo the ablation they will be monitored and at the end of 6 months of participation may choose to have the PVC ablation. If a deterioration may occur patients in the control group can have an ablation earlier.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Ventricular Contractions, Congestive Heart Failure
Keywords
ablations, CHF, PVC

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
3 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ablation procedure vs medical therapy
Arm Type
Active Comparator
Arm Description
PVC ablation vs medical therapy
Arm Title
Compare 2 arms for safety, symptoms
Arm Type
No Intervention
Arm Description
Compare control of PVC's between 2 groups.
Intervention Type
Device
Intervention Name(s)
PVC ablation
Other Intervention Name(s)
Surround Flow ablation catheters- Biosense Webster
Intervention Description
This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
Primary Outcome Measure Information:
Title
Change of Left Ventricular Ejection Fraction Measured With Simpson's Rule Expressed in Percent From Pre to Post Intervention
Description
Left ventricular ejection fraction with Simpson's Rule. This is a measurement obtained on an echocardiogram. It reflects the percentage of blood that is ejected from the heart with each beat. The mean change in ejection fraction will be compared for the 2 groups
Time Frame
Change between 0 and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with reduced ejection fraction (EF ≤45%) demonstrated by transthoracic echocardiogram and deemed to be non-ischemic by nuclear stress test or cardiac catheterization. Patients with >20% PVCs on 24 hour holter-recording Patient is 18 years of age or older Optimized medical therapy on stable therapy for minimum 3 months with no changes in beta-blocker, ACE-I/ARB, digoxin doses (varying diuretic doses permitted). Exclusion Criteria: Patients who are under the age of 18 years of age Patients with >2 dominant PVC morphologies Patients with cardiac surgery in previous 3 months or scheduled for following 6 months Patients who were implanted with a biventricular device during the last three months or single/dual chamber device (with ventricular pacing >10%) during the last three months Significant symptoms associated with PVCs that would make favor immediate ablation Intracardiac mural thrombus or myxoma Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timm Dickfeld, MD
Organizational Affiliation
University of Maryland, College Park
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
University of Maryland Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
University maryland medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21229
Country
United States
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Facility Name
University of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109-311
Country
United States
Facility Name
Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210-1252
Country
United States
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
University of Quebec
City
Sainte-Foy
State/Province
Quebec
ZIP/Postal Code
G1V4G5
Country
Canada

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Early Elimination of Premature Ventricular Contractions in Heart Failure

We'll reach out to this number within 24 hrs